News Room
02 December 2011
CSL Behring Awards Lead Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders. CSL Behring has awarded more than $600,000 in grants to patient organizations since the LEAD program was established in 2008.
More.
05 November 2011
Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents
New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type II hereditary angioedema (HAE), a rare and serious genetic disorder. Study results show that the outcomes of treatment with C1-INH during acute HAE attacks in children and adolescents are comparable to the outcomes observed in adults. Results of the analysis will be presented today at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.
More.
20 October 2011
Americans With Rare Diseases Are Experiencing
Diminished Access To Health Care
CSL Behring announces publication of its
Key Issues Dialogue on “Access to Care” which addresses many of the practices that impede access to care for people with rare and serious medical disorders, and possible solutions. This discussion is especially relevant now as healthcare reform is being implemented to assure that people with rare diseases do not end up with reduced care as an unintended consequence.
More.
14 September 2011
Plasma Protein Therapies Month Raises Awareness of Rare Diseases And The Importance of Donating Plasma
Every year thousands of people in the United States who suffer with rare and serious disorders such as hemophilia, hereditary angioedema, von Willebrand disease, primary immune deficiencies and inherited respiratory disease receive lifesaving therapies derived from human plasma. These conditions affect people of all ages from children to the elderly, and from all ethnic, racial and socioeconomic backgrounds.
More.
22 June 2011
Stress-Relieving Tips for Families Living with a Serious Medical Condition
A chronic or rare illness can harm more than a person’s health, it can also affect the strongest of relationships. Because the ill partner isn’t feeling well, he or she may be prone to significant mood swings. If the caregiver is not able to adjust to these shifts in demeanor, the relationship can be strained and both parties can find themselves in a state of depression.
More.
07 June 2011
New Survey Finds Lack of Communication Between Women and Healthcare Providers About Symptoms of Dangerous Bleeding Disorder
While millions of women are experiencing symptoms that could indicate a serious bleeding disorder, nearly half of them are not discussing those symptoms with their healthcare provider, according to new survey findings. The American Academy of Nurse Practitioners® (AANP) commissioned an online survey to gauge whether women experience, recognize and seek treatment for the five signs and symptoms of von Willebrand disease (VWD), one of the most common hereditary bleeding disorders. The survey, conducted by Harris Interactive, is part of an ongoing VWD awareness campaign by the AANP to help educate women experiencing the five signs and symptoms, and their healthcare providers, about this potentially life-threatening and underdiagnosed condition.
More.
17 May 2011
National Organization For Rare Disorders Presents
CSL Behring With 2011 Corporate Award
CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX:CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "
new treatments brought to market for patients with rare diseases."
More.
20 April 2011
Early Diagnosis and Treatment the Focus of International Dialogue on Primary Immunodeficiency Disease
Thought leaders from the medical, scientific and patient advocacy communities gathered in New York and London for CSL Behring's
Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies. They found common ground between the US and Europe on access-to-care issues such as early diagnosis and treatment of primary immunodeficiency disease (PID) and explored possible ways of improving patient care.
More.
19 April 2011
When is a Cold Not Just a Cold?
For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can pass illnesses back and forth. The Centers for Disease Control and Prevention estimates that children have about two to nine illnesses per year, nearly double the number of colds adolescents and adults experience during the same timeframe.
More.
06 April 2011
Deadline for LEAD Grant Proposals is April 30, 2011
CSL Behring, a global leader in the plasma protein biotherapeutics industry, is accepting grant requests through its Local Empowerment for Advocacy Development (LEAD) program through April 30, 2011. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
More.
24 February 2011
CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® to 30 Months
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra
®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 24 months to 30 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S., is the only SCIg in the U.S. that can be stored at room temperature throughout its entire shelf life.
More.
18 February 2011
CSL Behring Receives FDA Approval of Corifact™ for Treatment of Congenital Factor XIII Deficiency
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin
®- P, is the first and only FXIII concentrate approved in the U.S.
More.